Myeloid Maturity: ATRA to Enhance Anti-PD-1?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36656164.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3652 and PMC identifier 10073251.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Myeloid-derived suppressor cells (MDSC) are associated with resistance to anti-PD-1 therapies. All-trans retinoic acid (ATRA) may induce maturation of MDSCs and alter their immunosuppressive effects. Adding ATRA to pembrolizumab may target this resistance mechanism to enhance the overall impact of anti-PD-1-based immunotherapy. See related article by Tobin et al., p. 1209.
Medical subject headings
- Myeloid-Derived Suppressor Cells
- Melanoma